Business
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness.The
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"text","content":"The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness.The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date.Enrollment is planned to begin in summer 2024.The Journal of Infectious Diseases has published a letter outlining the planned trial protocol. WASHINGTON, May 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that a letter, titled Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients, authored by the Company’s Chief Executive Officer, Geoff Dow, PhD, has been published in the Journal of Infectious Diseases. Dr. Dow’s letter responds to comments made on a recent article published in the Journal, “Tafenoquine-atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human babesiosis.” Those comments, by M Liu M, EM Galon EM, S Ji, and X Xuan, called for more published medical literature on safely and effectively treating babesiosis. Dr. Dow’s response to those comments outlines plans by 60 Degrees Pharmaceuticals to launch a clinical trial to study the use of tafenoquine in treating human babesiosis. The Company plans to begin enrolling babesiosis patients this summer. The study will be the first and only of its kind in the United States to date. “A significant unmet medical need exists in North America, Europe, and Northeast Asia for new or improved methods of treatment and prevention of all forms of babesiosis, and for clinical trials dedicated to that end,” said Dr. Dow. “In close consultation with key opinion leaders in the field, we recently submitted a clinical protocol to the Food and Drug Administration. We are confident that the results of this study will add meaningfully to the global medical community’s understanding of this very serious, emerging, tick-borne infectious disease.” The 60 Degrees Pharmaceuticals babesiosis study protocol evaluates a triple combination of 800 milligrams of tafenoquine plus the recommended standard of care – which is atovaquone-azithromycin for at least 10 days...